-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, Renhe Pharmaceutical announced that its subsidiary Jiangxi Pharmaceutical has recently received the "Drug Registration Certificate" for Entecavir tablets approved and issued by the State Drug Administration.
Entecavir tablets product indications are: This product is suitable for the treatment of chronic adult hepatitis B (including compensation and Patients with liver disease in decompensated stage).
The acceptance time for Renhe's first submission of the production application for this product is June 12, 2019 (acceptance number: CYHS1900411).